X0306 4 2017-10-23 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001488637 Sheehy Douglas T. AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005-1884 0 1 0 0 See Remarks Common Stock, $0.0001 par value 2017-10-23 4 M 0 34300 12.95 A 34300 D Common Stock, $0.0001 par value 2017-10-23 4 S 0 22964 33.2509 D 11336 D Common Stock, $0.0001 par value 2017-10-23 4 S 0 5003 34.1273 D 6333 D Common Stock, $0.0001 par value 2017-10-23 4 S 0 6333 35.3428 D 0 D Common Stock, $0.0001 par value 2017-10-23 4 M 0 13125 19.63 A 13125 D Common Stock, $0.0001 par value 2017-10-23 4 S 0 7500 35.6334 D 5625 D Common Stock, $0.0001 par value 2017-10-23 4 S 0 5625 37.00 D 0 D Stock Option (right to buy) 12.95 2017-10-23 4 M 0 34300 0.00 D 2026-04-29 Common Stock 34300 75700 D Stock Option (right to buy) 19.63 2017-10-23 4 M 0 13125 0.00 D 2027-02-24 Common Stock 13125 76875 D This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. The transaction was executed in multiple trades in prices ranging from $32.79 to $33.78, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. The transaction was executed in multiple trades in prices ranging from $33.80 to $34.79, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. The transaction was executed in multiple trades in prices ranging from $34.80 to $35.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. The transaction was executed in multiple trades in prices ranging from $35.55 to $36.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 4, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from February 24, 2017, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. General Counsel and Corporate Secretary /s/ Douglas T. Sheehy 2017-10-25